The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rhee, Moo-Yong | - |
dc.contributor.author | Ahn, Taehoon | - |
dc.contributor.author | Chang, Kiyuk | - |
dc.contributor.author | Chae, Shung Chull | - |
dc.contributor.author | Yang, Tae-Hyun | - |
dc.contributor.author | Shim, Wan Joo | - |
dc.contributor.author | Kang, Tae Soo | - |
dc.contributor.author | Ryu, Jae-Kean | - |
dc.contributor.author | Nah, Deuk-Young | - |
dc.contributor.author | Park, Tae-Ho | - |
dc.contributor.author | Chae, In-Ho | - |
dc.contributor.author | Park, Seung Woo | - |
dc.contributor.author | Lee, Hae-Young | - |
dc.contributor.author | Tahk, Seung-Jea | - |
dc.contributor.author | Yoon, Young Won | - |
dc.contributor.author | Shim, Chi Young | - |
dc.contributor.author | Shin, Dong-Gu | - |
dc.contributor.author | Seo, Hong Seog | - |
dc.contributor.author | Lee, Sung Yun | - |
dc.contributor.author | Kim, Doo Il | - |
dc.contributor.author | Kwan, Jun | - |
dc.contributor.author | Joo, Seung-Jae | - |
dc.contributor.author | Jeong, Myung Ho | - |
dc.contributor.author | Jeong, Jin-Ok | - |
dc.contributor.author | Sung, Ki Chul | - |
dc.contributor.author | Kim, Seok Yeon | - |
dc.contributor.author | Kim, Sang-Hyun | - |
dc.contributor.author | Chun, Kook-Jin | - |
dc.contributor.author | Oh, Dong Joo | - |
dc.date.accessioned | 2021-09-03T11:03:21Z | - |
dc.date.available | 2021-09-03T11:03:21Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-01-05 | - |
dc.identifier.issn | 2050-6511 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/84943 | - |
dc.description.abstract | Background: Hypertension and dyslipidemia are major risk factors of cardiovascular disease (CVD) events. The objective of this study was to evaluate the efficacy and safety of the co-administration of fimasartan and rosuvastatin in patients with hypertension and hypercholesterolemia. Methods: We conducted a randomized double-blind and parallel-group trial. Patients who met eligible criteria after 4 weeks of therapeutic life change were randomly assigned to the following groups. 1) co-administration of fimasartan 120 mg/rosuvastatin 20 mg (FMS/RSV), 2) fimasartan 120 mg (FMS) alone 3) rosuvastatin 20 mg (RSV) alone. Drugs were administered once daily for 8 weeks. Results: Of 140 randomized patients, 135 for whom efficacy data were available were analyzed. After 8 weeks of treatment, the FMS/RSV treatment group showed greater reductions in sitting systolic (siSBP) and diastolic (siDBP) blood pressures than those in the group receiving RSV alone (both p < 0.001). Reductions in siSBP and siDBP were not significantly different between the FMS/RSV and FMS alone groups (p = 0.500 and p = 0.734, respectively). After 8 weeks of treatment, FMS/RSV treatment showed greater efficacy in percentage reduction of low-density lipoprotein cholesterol (LDL-C) level from baseline than that shown by FMS alone treatment (p < 0.001). The response rates of siSBP with FMS/RSV, FMS alone, and RSV alone treatments were 65.22, 55.56, and 34.09%, respectively (FMS/RSV vs. RSV, p = 0.006). The LDL-C goal attainment rates with FMS/RSV, RSV alone, and FMS alone treatments were 80.43%, 81.82%, and 15.56%, respectively (FMS/RSV vs. FMS, p < 0.001). Incidence of adverse drug reactions with FMS/RSV treatment was 8.33%, which was similar to those associated with FMS and RSV alone treatments. Conclusion: This study demonstrated that the co-administration of fimasartan and rosuvastatin to patients with both hypertension and hypercholesterolemia was efficacious and safe. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.subject | FIXED-DOSE COMBINATIONS | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | BLOOD-PRESSURE | - |
dc.subject | KOREAN PATIENTS | - |
dc.subject | ADHERENCE | - |
dc.subject | PHARMACOKINETICS | - |
dc.subject | TOLERABILITY | - |
dc.subject | MULTICENTER | - |
dc.subject | CHOLESTEROL | - |
dc.subject | POPULATION | - |
dc.title | The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Shim, Wan Joo | - |
dc.contributor.affiliatedAuthor | Seo, Hong Seog | - |
dc.identifier.doi | 10.1186/s40360-016-0112-7 | - |
dc.identifier.scopusid | 2-s2.0-85008413171 | - |
dc.identifier.wosid | 000391738800002 | - |
dc.identifier.bibliographicCitation | BMC PHARMACOLOGY & TOXICOLOGY, v.18 | - |
dc.relation.isPartOf | BMC PHARMACOLOGY & TOXICOLOGY | - |
dc.citation.title | BMC PHARMACOLOGY & TOXICOLOGY | - |
dc.citation.volume | 18 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Toxicology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Toxicology | - |
dc.subject.keywordPlus | FIXED-DOSE COMBINATIONS | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | BLOOD-PRESSURE | - |
dc.subject.keywordPlus | KOREAN PATIENTS | - |
dc.subject.keywordPlus | ADHERENCE | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | TOLERABILITY | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | CHOLESTEROL | - |
dc.subject.keywordPlus | POPULATION | - |
dc.subject.keywordAuthor | Fimasartan | - |
dc.subject.keywordAuthor | Rosuvastatin | - |
dc.subject.keywordAuthor | Hypertension | - |
dc.subject.keywordAuthor | Hypercholesterolemia | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.